Intellia Therapeutics Files 8-K for Financials
Ticker: NTLA · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1652130
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: NTLA
TL;DR
Intellia Therapeutics filed an 8-K on Nov 7, 2024, reporting financial condition and results.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but serves as a notification of these items.
Why It Matters
This 8-K filing indicates that Intellia Therapeutics is providing updates on its financial condition and results of operations to the SEC, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — This filing is a standard procedural report and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- November 07, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-37766 (company_id) — Commission File Number
- 36-4785571 (company_id) — IRS Employer Identification No.
- 40 Erie Street, Suite 130 (address) — Principal Executive Offices
- Cambridge (city) — Principal Executive Offices
- Massachusetts (state) — Principal Executive Offices
- 02139 (zip_code) — Principal Executive Offices
- 857 285-6200 (phone_number) — Registrant's Telephone Number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated November 07, 2024.
What is the full legal name of the company filing this report?
The full legal name of the company is Intellia Therapeutics, Inc.
In which U.S. state was Intellia Therapeutics, Inc. incorporated?
Intellia Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Intellia Therapeutics, Inc.?
The Commission File Number is 001-37766.
What is the primary business address listed for Intellia Therapeutics, Inc.?
The primary business address is 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-07 07:45:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
Filing Documents
- ntla-20241107.htm (8-K) — 42KB
- ntla-ex99_1.htm (EX-99.1) — 153KB
- img149557450_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-122810.txt ( ) — 337KB
- ntla-20241107.xsd (EX-101.SCH) — 24KB
- ntla-20241107_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 7, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K. The information in this report furnished pursuant to Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report .
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated November 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: November 7, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President